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Abstract 
Objective: Previous studies have suggested that there is a reciprocal relationship 
betweenanxiety/depression and insomnia. However, little is known about the prospective 
relationships between these constructs across the course of cognitive behavioural therapy 
(CBT). The present study examined these relationships in clients who received short-term 
cognitive behavioral therapy in a primary care setting. 
Methods: 653 clients (mean age = 37.8 [12.9], 26.4% men)with mild to moderate levels of 
anxiety and depression and a treatment duration of at least 7 weeks were included for 
analyses.The clients completed questionnaires measuring mixed anxiety-depression (MAD - 
Patient Health Questionnaire Anxiety and Depression Scale) and insomnia (3 items derived 
from the Karolinska Sleep Questionnaire representing core DSM-V criteria) on a session-to-
session basis. The data were analysed using latent growth curve models and random intercept 
cross-lagged panel models. 
Results: The results of the latent growth curve models showed that there was a significant 
decrease in both mixed anxiety-depression (cubic slope; B=.002, p<.001, quadratic slope;
B=.036, p<.001, linear slope; B= -.205, p<.001) and insomnia (linear slope; B= -.080, 
p<.001) across treatment. A strong correlation (r=.838, p<.001) between the linear slopes 
indicated co-occurring change processes. The cross-lagged panel model showed that 
insomnia significantly predicted mixed anxiety-depression at the subsequent measurements 
(B=.190; p<.001), but not vice versa (B=.252; p=.343). 
Conclusions: Changes in mixed anxiety-depression and insomnia are co-occurring processes 
during the course of CBT. Changes in insomnia predicted prospectively changes in mixed 
anxiety-depression, but not vice versa. Targeting insomniain the context of brief CBT in 
clients with mild to moderate anxiety and depression may thereforenot only further reduce 
symptoms of insomnia,but also symptoms of anxiety and depression.
Keywords: insomnia, anxiety, depression, cognitive behavioral therapy 
List all acronyms 
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RI-CLPM = Random Intercept Cross Lagged Panel Model 
RMSEA = Root Mean Square Error of Approximation 
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Introduction 
Sleep and mental health problems are growing public health concerns, affecting millions of 
people around the world. Insomnia is the most common sleep disorder, with a prevalence of 
10-15% in the general population(1, 2). Anxiety disorders and depression are the most 
common mental health disorders. Meta-analyses have estimated that the global prevalence of 
anxiety disorders is around 7% (3), whereas about 5% of the population has a major 
depressive disorder (4). Single studies applying less stringent criteria for classifying 
insomnia, anxiety and depression often report higher estimates, and comorbidity between 
these disorders are common (5, 6).  
Traditionally, researchers and therapists have perceived insomnia as secondary to mental 
health problems such as depression and anxiety. However, the last decadesthere has been an 
increasing focus on insomnia as a primary diagnosis and as a predictor of poor mental health. 
Non-depressed individuals with insomnia have twice the risk of developing a depressive 
episode compared to non-depressed individuals without insomnia (7). Research also indicates 
that insomnia predicts anxiety (for a review, see 8). Several studies have found evidence for a 
bidirectional relationship between insomnia on the one hand and depression and anxiety on 
the other. Jansson-Frøjmark and Lindblom (9) found that anxiety and depression at baseline 
each increased the risk of new insomnia cases at follow-up one year later, whereas insomnia 
at baseline in turn increased the risk of new cases of anxiety and depression at follow-up. 
Sivertsen et al. (10) found that having either insomnia or depression at both baseline and 
follow-up entailed a six-fold risk of having developed the other disorder at follow-up. In a 
systematic review of studies on this topic, Alvaro, Roberts, & Harris (11)reported that the 
evidence thus far suggests a bidirectional relationship, although more longitudinal studies are 
needed to draw a definitive conclusion. 
The aforementioned studies were primarily based on cohort designs with relatively long time-
lags, typically using year as unit of measurement for time. Shorter time-lags would be of 
interest in situations when more rapid changes are to be expected, such as changes following 
an intervention.Cognitive Behavioural Therapy for insomnia (CBT-I) has been successful in 
the treatment of primary (12) and comorbid (13) insomnia, as well as reducing levels of both 
anxiety and depression (14, 15). Conversely, CBT for depression and anxiety also has an 
effect on insomnia. For example, Mason and Harvey (16) found that Internet-based CBT for 
anxiety and/or depression was associated with a decrease in anxiety and depression as well as 
in insomnia symptoms, and Carney and co-workers (17) reported a significant decrease of 
insomnia following CBT treatment for depression. However, in the latter study half of those 
with a pre-treatment insomnia diagnosis still had residual insomnia post-treatment, despite 
remitting from depression.   
To the best of our knowledge, no studies have measured both insomnia and 
anxiety/depressive symptoms repeatedly throughout the course of CBT treatment to 
investigate trajectories of these symptoms (how each develops over time) and the 
relationship between these two processes. There are, however, studies that have examined 
trajectories of depressive symptoms across treatment. Gunthert, Cohen (18) and Kashdan and 
Roberts (19) found that symptom relief throughout the course of cognitive therapy and group 
CBTwas best described as curvilinear, with an initial drop before levelling off. Furthermore, 
we are not familiar with any studies that have explored cross-lagged relations between 
insomnia and anxiety/depression from session to session during treatment (whether insomnia 
at one session predict anxiety/depression at the subsequent session and vice versa). However, 
there are studies that have examined cross-lagged relations between other measures over the 
course of CBT treatment, such as the relationship between fear, avoidance and physiological 
symptoms across CBT for social anxiety disorder (20). 
It should be noted that  many studies applying cross-lagged panel models do not account for 
stable individual differences, and thus fail to represent genuine within-person relations across 
time(21). The consequence may be inaccurate estimates of the reciprocal effects which may 
lead to false conclusions regarding the underlying causal relations between variables. As 
shown by Hamaker et al. (21), this can be avoided by separating the within-person process 
from stable between-person differences by means of a multilevel approach in which 
measurement occasions are nested within individuals. 
For the current study, data from the Prompt Mental Health Care (PMHC) project were 
used(22, 23). PMHC is modelled after the English program Improving Access to 
Psychological Therapies (IAPT) (24), and is a free-of-charge, low-threshold, primary health 
care program, aimed at reaching adults with anxiety and mild to moderate levels of 
depression. Cognitive behavioural therapy (CBT) is provided by multidisciplinary teams of 
health care professionals. Therapy modes include face-to-face, group and guided self-help 
treatments, offered through a matched care model. Session-to-session data were collected as 
part of the evaluation of the PMHC program. A previous study based on the same dataset 
showed that the program was associated with a clinically significant improvement in 
symptoms of anxiety and depression from pre-to post-treatment. The reliable recovery rate 
was 51.6%(23), which is on par with the IAPT target recovery rate (24). The session-to-
session data were employedto investigate the trajectories of symptoms of mixed anxiety-
depression (MAD) and insomniaover the course of treatment, using latent growth curve 
modelling. Based on preliminary analyses, we expected a linear-driven improvement during 
the course of treatment for both symptoms of mixed anxiety-depression (MAD) and 
insomnia(22). Furthermore, we explored cross-lagged relations between MADand insomnia 
from session to session, using a random intercept cross lagged panel model (RI-CLPM) (21),
to see whether the relationship between MAD and insomnia could best be described as 
unidirectional or as reciprocal. Based on current evidence, we expected the latter. 
Methods 
Pilot samples 
The study included 12 pilot sites, distributed across several geographical areas, both urban 
and rural, in Eastern, Western and Central Norway. All PMHC teams were interdisciplinary, 
and each team had at least one psychologist who carried the professional responsibility for 
the services provided. All employees had a minimum of three years with relevant higher 
education, and completed an additional one-year training in cognitive behavioural therapy 
under the auspices of the Norwegian Association for Cognitive Therapy. The CBT provided 
to the clients primarily focused on depression and anxiety symptoms. Central elements of 
CBT-I (sleep diary, stimulus control) were used very little in PMHC (<5%).  
Procedures 
All clients participated in an initial assessment. During these sessions, information about the 
study and treatment was provided to the clients, and the therapist collected the necessary data 
to decide whether PMHC could be the appropriate treatment. The therapist identified the 
relevance and severity of the mental problems, and the available client resources. A formal 
diagnosis was not provided. Clients with suspected or known severe psychiatric disorders,
severe substance abuse, and suicide risk were generally excluded from PMHC, and were 
referred to the general practitioner or more specialized mental health care services.   
Participation was based on opt-in, where all eligible clients were invited, and informed 
written consent was obtained from each participant upon recruitment. The study was 
approved by the regional ethics committee for Western Norway (REK-vest 2014/597). For 
the present study, a prospective cohort design was used. The participants were asked to 
complete questionnaires at pre-treatment, before each session during the treatment, and at 
post-treatment. For each participant, the therapists were asked to complete a questionnaire at 
post-treatment about the therapy process.   
Participants 
Of the 1983 clients that received treatment at PMHC between October 2014 and April 2016,
1279 participated in the study, resulting in an overall participation rate of 64.5%. By April 
2016, 970 participating clients had concluded treatment. For the present study, we aimed to 
examine the development of MAD and insomnia during the first 8 weeks of treatment. Eight 
weeks was chosen as a trade-off between substantial treatment duration and reasonable 
sample size. The observations of the included participantswere divided into time intervals as 
follows: T1=0 weeks (n=652, Mtime=0, SD=0), T2=2 ±1weeks (n=325, Mtime=2.1, SD=.5), 
T3=4 ± 1 weeks (n=318, Mtime=4.1, SD=.5), T4=6 ± 1 weeks (n=300, Mtime=6.1, SD=.5), and 
T5=8 ± 1 weeks (n=300, Mtime=8.1, SD=.5). Measurements were averaged within a time 
interval in case a client had multiple observations within that specific interval. Clients with a 
treatment duration less than 7 weeks were excluded (n=118), as were clients for which the 
treatment duration was unknown due to missing data in the therapist questionnaire (n=199), 
leaving a total of n=653 clients for further analyses.The final sample (n=653) was 
comparable to the overall sample (n=970) with regard to sex, age, educational level (low, 
medium, high), marital status (having a partner vs. not having a partner), immigration 
background (defined as the clients or his/her parents being born outside Norway), 
baseline (all p>.05). For the final sample (n=653), 
based on the demographic variables mentioned above, and longitudinal MAD/Insomniadata 
with missing values (T1-T5)produced a non-significant chi-squared 2(350)=330.6, 
p=.77), which may point to follow-up data missing completely at random.  
Measures
The Patient Health Questionnaire Anxiety and Depression Scale (PHQ-ADS) was used to 
measure MAD (25). The PHQ-ADS includes 16 items based on each of the DSM-IV criteria 
mation purposes, the 
sum score was averaged by the number of items. The PHQ-ADS has shown good 
psychometric properties (25). 
MAD was modeled as a manifest variable. 
Symptoms of insomnia (labeled insomnia throughout the manuscript) were assessed by three 
items derived from the validated Karolinska Sleep Questionnaire (26). These core insomnia 
symptoms are based on the DSM-V criteria for insomnia disorder, which include 1) 
difficulties initiating sleep (sleep onset problems), 2) experiencing frequent nocturnal 
awakenings (sleep maintenance problems) and 3) daytime tiredness/sleepiness (functional 
impairment caused by the sleep problem). These items are also included in The Research 
Diagnostic Criteria for insomnia (27). All items were measured on a scale from 0 to 7 days, 
yielding a total score range of 0-21. Previous studies have used these three items as a 
continuous score as well (28, 29). 
Given this relatively low value for internal consistency, insomnia was modeled as a latent 
variable.Longitudinal measurement invariance (MI) was found for latent insomnia after 
testing and sequentially comparing configural, metric, scalar, residual, factor variance, and 
factor covariance invariance models. Results indicated that the intercept for item 3 at T1 and 
the factor covariances (ft2, ft3) and (ft4, ft5) should be estimated freely. All other parameters 
were constrained to be equal across time points in subsequent analyses.  
Employment status was assessed by means of two questions, one multi-response item about 
employment status, and one multi-response item about sources of income (22). Based on 
these two questions, participants were placed into three categories: 1) in regular work, 2) in 
combined work and recipients of benefits, and 3) out of work with or without benefits. A 
similar categorization has been used in another Norwegian treatment study (30).   
Statistical analyses 
Descriptive statistics were calculated for manifest baseline and outcome variables. 
Intercorrelations were calculated for MAD and insomnia across time.  
All subsequent models were estimated using full information maximum likelihood (FIML) 
estimation under the assumption of data missing at random (MAR) with robust standard 
errors (MLR). Model fit was assessed by using the Comparative Fit Index (CFI), the Root 
Mean Square Error of Approximation (RMSEA), and the Standardized Root Mean Square 
Residual (SRMR). A CFI considered indicative of 
good model fit(31). To compare nested models, we used the following guidelines based on 
the recommendations by Chen (32) -.010 in CFI, supplemented by a change of 
 in SRMR would support the less restricted model 
(restricted model minus unrestricted model).  
Unconditional growth models were estimated separately for MAD and insomnia over the five 
time points. Intercept only, linear, quadratic, and cubic functional forms were sequentially 
tested against each other using the same criteria for fit indices as described above. After 
establishing the best fitting unconditional growth models for MAD and insomnia, baseline 
covariates were added to examine whether these were associated with the individual growth 
factors. Unconditional and conditional parallel process models were estimated as well to 
determine whether the change processes of MAD and insomnia were co-occurring.  
To estimate reciprocal relationships over time, a random intercept cross-lagged panel model 
was fitted to the data (21). As displayed in figure 2 the RI-CLPM model distinguishes 
between variance at the between-level and variance at the within-level to avoid ecological 
fallacy. All means were unconstrained with exception of mean insomnia at T1, which was set 
to zero for the purpose of identification as our model used latent insomnia scores instead of 
manifest insomnia scores. All other specifications were similar to previous applications of 
this model (21, 33, 34). 
The random intercepts represented stable trait-like, relative individual differences for MAD 
and insomnia during the 8-weeks treatment period. The cross-lagged parameters indicated the 
extent to which deviations from an individual s expected MAD score could be predicted from 
preceding deviations from this i  insomnia score while accounting for the 
 Expected 
scores for individual i at time t are defined as the temporal group mean at time tplus the 
ait-like deviations from this group mean as modelled by the random intercept.  
The Statistical Package for Social Science version 23 for Windows and Mplus version 
7.4were used for data analyses. 
Results 
Baseline characteristics and correlations 
Of the 653 participants included in this study, 26.4% (n=170) were men. The average age 
was 37.8 (SD=12.9), and 37.9% (n=244) of the participants did not have a partner. With 
regard to educational level, 9.3% (n=60) of the sample had primary education only, 44.2%
(n=285) had high school education, whereas 46.5% (n=300) had higher education. The 
percentage of participants with an immigrant background was 9.4% (n=61). Finally, 40.5% 
(n=261) was in regular work, 35.0% (n=226) in combined work and recipients of benefits, 
and 24.5% (n=158) was out of work with or without benefits. The average MAD score was 
1.40 (SD=0.60) at baseline, while the average insomnia score was 3.73 (SD=1.92). For MAD
(1.40 * 16 items = 22.40), this reflected symptoms at the moderate level(25), which is in line 
with the intended target population of PMHC and IAPT (23, 24). A similar categorization 
was difficult for the insomnia score as established norms were not available. Still, the average 
insomnia score in the current sample was higher than among healthy Swedish adults (rescaled 
average = 2.8)(29).
Observed means based on manifest scores with regard to MAD and insomnia indicated a 
monotone decrease between T1 (MADt1=1.40, SD=.60; Insomniat1=3.73, SD=1.92) and T5 
(MADt5=.90, SD=.59; Insomniat5=3.01, SD=2.02). According to conventional guidelines, this 
-week treatment period.High correlations 
between time points with regard to respectively MA  insomnia 
indicated relatively high degrees of stability across time. Correlations between MAD and 
insomnia . 
As the data was collected at multiple sites (average cluster size = 54), intraclass correlations 
(ICCs) were calculated for the outcomes variables at each time point. 
very low (<.01), and accounting for the cluster effect of pilot site was therefore considered 
unnecessary. 
Growth curve models for mixed anxiety-depression and insomnia 
The best functional form for the unconditional MAD model was cubic with mean intercept 
(SE) = 1.402 (.023), mean linear slope = -.205 (.018), mean quadratic slope = .036 (.006), and 
mean cubic slope = -.002 (.000) (see Table S1, Supplemental Digital Content, 
http://links.lww.com/PSYMED/A542). For this model, the variance of the cubic slope factor 
was constrained to zero to avoid non-convergence. The trajectory of MAD was characterized 
by a monotone decrease during the 8-weeks treatment period with the decrease during the 
first two weeks being largest (see Figure 1). The best functional form for the unconditional 
insomnia model was linear with mean intercept = .000 (by default due to the latent variable 
specification) and mean linear slope = -.080 (.010), see figure 1 and Table S1, Supplemental 
Digital Content, http://links.lww.com/PSYMED/A542). This indicated a linear decrease in 
insomnia during the 8-weeks treatment period. 
In the next step, baseline predictors were added to the selected growth curve models (Table 
1). For MAD (CFI=1.000, RMSEA=.000, SRMR=.010), younger age, immigration 
background, and being in combined work and recipient of benefits was associated with higher 
levels of MAD at baseline. Immigration background was also associated with a lower linear 
slope. Together with the higher average baseline levels, this may indicate that treatment was 
less effective for clients with an immigrant background. For insomnia (CFI=.958, 
RMSEA=.034, SRMR=.046), female sex and being in combined work and recipient of 
benefits were associated with higher levels of insomnia at baseline.  
Both the unconditional and the conditional parallel process models showed good model fit 
(see Table S2, Supplemental Digital Content, http://links.lww.com/PSYMED/A542). There 
was a strong significant correlation between the intercepts of MAD and insomnia indicating 
that clients with high levels of MAD at baseline were also more likely to have high levels of 
insomnia at baseline (rcond=.838, p<.001). Similarly, there was a strong correlation between 
the linear slope parameters of MAD and insomnia, indicating that these two change processes 
were co-occurring and shared about 57% of their linear change variance (rcond=.758, p<.001). 
All other associations between the growth parameters of these two processes were not 
statistically significant (Table S2). It should be noted that the variance of the quadratic and 
cubic MAD slope factors were constrained to zero in both models to avoid convergence 
problems.  
Random intercept cross-lagged panel model (RI-CLPM) for mixed anxiety-depression and 
insomnia 
The unconditional RI-CLPM with unconstrained autoregressive and cross-lagged parameters 
showed adequate model fit (CFI=.986, RMSEA=.025, SRMR=.044) and served as a base 
model for the comparison with more constrained models. The subsequent models with 
constrained autoregressive parameters - , and 
constrained autoregressive &cross-lagged parameters -
fitted the data equally well as the base model. Therefore, the most restrictive 
model with constrained autoregressive & cross-lagged parameters was used to examine the 
parameters of interest in further detail. 
Between 48.8% to 52.8% of the variance of MAD was explained at the between level. For 
insomnia, this percentage was between 50.0% and 60.5%.As displayed in Table 2, the results 
showed a strong correlation between MAD and insomnia at the between-person level (r=.601, 
p<.001). This correlation reflects stable between-client traits during the 8-weeks treatment 
period. That is, clients with higher average levels of MAD also showed higher average levels 
of insomnia. 
There was a large correlation at the within-level at T1 (r=.622, p<.001). This indicates that 
the client  individual deviation from their own expected score on MAD at baseline was 
st deviation from their own expected score on insomnia at 
baseline. The residual correlations from T2 to T5 were also high (r>.55, all p<.001), 
indicating that the within-person changes in MAD were strongly associated with the within-
person changes in insomnia, and arelinked through other, unmeasured time-varying variables.  
For both MAD and insomnia, the stability paths were positive and statistically significant 
(Table 2). This indicated that a client scoring above (or below) his/her expected score at one 
occasion was likely to score above (or below) his/her expected score at the next occasion. In 
addition, statistically significant cross-paths were found for insomnia (t-1) to MAD (t). That 
is within-person changes in insomnia predict within-person changes in MAD (B=.190, 
S.E.=.034, p<.001, see also T
accounting for time-variant and time-invariant stability. Cross-paths in the opposite direction, 
MAD (t-1) to insomnia (t), were not statistically significant (B=.252, S.E.=.265, p=.34, see 
also Table 2). 
Discussion 
Our main findings from the latent growth curve models were, as expected, a decrease in
insomnia (linear) and MAD (cubic) over the course of treatment. The latter is in line with 
studies that have reported a curvilinear trend for depressive symptoms over the course of 
treatment (18, 19). The mean observed scores on the PHQ-ADS indicate that the severity of 
MAD in the sample on average was moderate at baseline and mild at the end of treatment. A 
decrease in symptoms of both MAD and insomnia from baseline to the end of treatment is in 
line with what Mason and Harvey (16) reported from their study on internet-based CBT for 
anxiety and/or depression. The steeper decrease in MAD compared to the decrease in
insomnia may reflect that the treatment was mainly targeted towards anxiety and/or 
depression. 
The significant positive correlation between the intercepts of MAD and insomnia is in line 
with research reporting positive correlations or high prevalence of comorbidity between 
insomnia and mental distress(5-7, 9-11). The positive correlation between the linear slopes of 
MAD and insomnia may indicate a causal link whereby one or both of the processes 
influence the other, or alternatively that a third variable affect both processes. For the present 
study, receiving CBT treatment was likely to be one such a process. 
We found that younger clients had higher levels of MAD compared to older clients. Despite 
some conflicting findings in the literature and the question of possible cohort effects, a 
literature review reported that there is some evidence for a decrease in anxiety and depression 
across the adult life span (35). Clients with an immigration background also had higher levels 
of MAD. Immigrants in Norway are reported to have poorer mental health compared to 
ethnic Norwegians (36), and they are often less likely to seek help for mental health problems 
(37). When it comes to insomnia, women had higher levels than men did. There is compelling 
evidence that women have an increased risk of insomnia compared to men (38). We did not 
find many indications that treatment response varied according to client characteristics. The 
exception was for immigrant background, in that clients with an immigration background had 
a slower rate of change in MAD. This may indicate a lower treatment response in these 
clients. Treatment response may be affected by factors such as communication difficulties 
between t
(39).  
Our main finding from the cross-lagged analyses was that insomnia predicted MAD at the 
subsequent time point, but not vice versa. Thus, we did not find evidence for a bidirectional 
relationship between insomnia and MAD, contrary to what has been reported from previous 
studies the last decade (9, 40). These studies used a time lag of one and eleven years, 
respectively, and they were not conducted in a therapeutic setting. Moreover, the 
aforementioned studies did not explicitly model within- and between-person processes, which 
may lead to biased estimates of reciprocal effects (21).  
Although previous studies have indicated that treatment was effective in reducing both 
mental health symptoms and insomnia(22, 23), the CBT provided to the clients was not 
specifically targeted towards insomnia (i.e., not CBT-I).Our finding that insomnia (t-1) 
predicted MAD (t) suggests that targeting insomniacould be an important part of treatment 
for anxiety and depression, because this may lead to a further decrease in both insomniaand 
MAD symptoms. Results from other studies have pointed in the same direction (41-44), most 
notably a recent large-scale randomized controlled trial among university students which 
found strong evidence thattreating insomnia leads to improved mental health(41). 
Strengths and limitations 
The main strengths of the present study are the collection of data at every session throughout 
treatment, a relatively large sample size, and the choice of methods to analyse these data. 
Numerous studies have examined the relationship between insomnia and anxiety/depression 
in the general population with a long time span, or in the clinical populationwith 
measurements pre and post treatment only.We examined cross-lagged relations between 
insomnia and MAD throughout the course of therapy using five repeated measurements. 
Structural equation modelling has several advantages compared to traditional approaches. 
These include the modelling of intra- and inter-individual differences, estimation of latent 
factors separated from error variance, and flexible methods for handling missing data (45).
Growth curve models permit investigating trajectories of symptoms and a RI-CLPM permits 
the investigation of genuine within-person cross-lagged relations across time. 
There are also some limitations to the present study. Symptom assessment of MAD and 
insomnia were based on self-report only. It cannot be excluded that, for example, insomnia 
scores were somewhat inaccurate due to possible mood-dependence. For the replication of 
the current findings, increasing measurement accuracy by means of additional modes of 
assessment (e.g. clinical interview, diaries, actigraphy) is recommended. Moreover, the 
insomnia measure did not include a specific item on early morning awakenings, which may 
have affected its construct validity.  
By investigating symptoms of mixed anxiety-depression rather than anxiety and depressive 
symptoms separately, there is a risk of missing important information concerning reciprocal 
relations that may be specific to the disorder. According to a retrospective population study, 
insomnia was in most cases present before or at the same time as symptoms of a mood 
disorder, whereas it was present at the same time or after an anxiety disorder(46).Similarly, in 
a study of adolescents with comorbid insomnia and depression/anxiety, insomnia occurred 
first in the majority of cases concerning depression, whereas it occurred after in the majority 
of cases concerning anxiety (47).  
In the previously mentioned longitudinal studies where bi-directionality was assessed (9, 40),
the Hospital Anxiety and Depression Scale (HADS) was used to measure anxiety and 
depression. A main difference between HADS and PHQ-ADS is that the latter includes one 
does not. Thus, there is some overlap between the two measures in the present study. 
However, a sensitivity analysis excluding the two items mentioned above had minimal 
impact on the results for the RI-CLPM (not shown).  
The sample consisted of clients with anxiety and mild to moderate depression, undergoing 
CBT of a relatively short duration. The current findings may therefore be particular relevant 
to clients receiving treatment in primary health care settings through programs similar to 
PMHC, but may not be generalizable to clients with more severe symptoms or longer 
treatment periods. Although the latter is a limitation in itself, it should be noted that the 
potential group of clients that could benefit from CBT treatment in primary health care is 
assumed large (48). Increasing the availability of programs such as PMHC is therefore 
important, not the least because many clients do not fulfil the criteria of severity of problems 
set by specialized mental health services. 
Generalizability to the entire target group of PMHC may be compromised due to the 
relatively low participation rate of 64.5%. Although data for non-participants were 
unavailable, some selection among participants seems reasonable to assume (e.g. more 
females, less severe symptoms at baseline). 
It has been shown that the length of the time lag can affect the cross-lagged regression 
coefficients (49). Finding the optimal time lag a-priori can be challenging as it depends on the 
actual size of the autoregressive and cross-lagged associations, which is typically information 
that is not available prior to data collection. In the present study, the intervals between 
occasions were on average 2 weeks. Based on the autoregressive and cross-lagged 
coefficients found in our study and the formula from Dormann & Griffin (49), the estimated 
optimal time lag was 1.22 weeks. This implies that the strength of our cross-lagged 
associations may be somewhat underestimated.  
Conclusions 
This study found that over the course of brief CBT, in clients with mild to moderate levels of 
MAD, changesin insomnia predict changes in symptoms of mixed anxiety-
depression, but not vice versa. Targeting insomnia in clients with comorbid insomnia and 
depression/anxiety may thus be vital for optimal effect of cognitive behavioural therapy for 
anxiety and/or depression. Based on our findings we recommend that therapists perform 
CBT-I or place larger emphasis on implementing elements from CBT-I in their therapeutic 
approach to clients with comorbid insomnia and anxiety/depression. 
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FIGURE CAPTION 
Figure 1. Unconditional average growth curves for mixed anxiety-depression and insomnia 
(bold line). The thin grey lines represent the estimated individual growth curves of 50 
randomly selected participants. 
Figure 2. Random intercept cross-lagged panel model of the relationship between mixed 
anxiety-depression and insomnia. 
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Table 2. Parameter estimates of the unconditional random intercept cross-lagged panel model 
(robust maximum likelihood, N=653).
Unstandardized
b (SE)
Standardized 
Autoregressive
Mad t2 ON Mad t1 .237 (.110)* .245 (.105)*
Mad t3 ON Mad t2 .237 (.110)* .249 (.116)*
Mad t4 ON Mad t3 .237 (.110)* .225 (.113)*
Mad t5 ON Mad t4 .237 (.110)* .239 (.111)*
Sleep t2 ON Sleep t1 .733 (.113)*** .593 (.115) ***
Sleep t3 ON Sleep t2 .733 (.113)*** .767 (.122) ***
Sleep t4 ON Sleep t3 .733 (.113)*** .700 (.109) ***
Sleep t5 ON Sleep t4 .733 (.113)*** .732 (.120) ***
Cross-lagged
Mad t2 ON Sleep t1 .190 (.034)*** .433 (.087)***
Mad t3 ON Sleep t2 .190 (.034)*** .562 (.104)***
Mad t4 ON Sleep t3 .190 (.034)*** .511 (.085)***
Mad t5 ON Sleep t4 .190 (.034)*** .541 (.089)***
Sleep t2 ON Mad t1 .252 (.265) .093 (.102)
Sleep t3 ON Mad t2 .252 (.265) .094 (.106)
Sleep t4 ON Mad t3 .252 (.265) .085 (.098)
Sleep t5 ON Mad t4 .252 (.265) .089 (.099)
Other
Association (Mad t1, Sleep t1) .254 (.100)** .622 (.094)***
Residual association (Mad t2, Sleep t2) .194 (.032)*** .666 (.063)***
Residual association (Mad t3, Sleep t3) .098 (.028)*** .647 (.100)***
Residual association (Mad t4, Sleep t4) .120 (.034)*** .555 (.105)***
Residual association (Mad t5, Sleep t5) .118 (.024)*** .616 (.093)***
Between-person association (Intercept MAD,
InterceptSLEEP)
.296 (.101)*** .601 (.087)***
Mad = mixed anxiety-depression; ***p<.001 **p<.01
*p<.05.
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